Merck (NYSE: MRK) announced topline results from the KEYNOTE-010 study of KEYTRUDA® (pembrolizumab) in advanced non-small-cell lung cancer (NSCLC) demonstrating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE